|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
|
US6759398B2
(en)
*
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
US6858596B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivative
|
|
GB0019172D0
(en)
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
ATE416184T1
(de)
*
|
2000-08-05 |
2008-12-15 |
Glaxo Group Ltd |
17.beta.-carbothioat 17.alpha.- arylkarbonyloxyloxy androstanderivate als anti- phlogistische medikamente
|
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
|
WO2002088167A1
(en)
|
2001-04-30 |
2002-11-07 |
Glaxo Group Limited |
Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
|
|
EP1395604B1
(en)
*
|
2001-06-12 |
2008-06-25 |
Glaxo Group Limited |
Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives
|
|
GB0125259D0
(en)
*
|
2001-10-20 |
2001-12-12 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0127160D0
(en)
*
|
2001-11-12 |
2002-01-02 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2003042229A1
(en)
*
|
2001-11-12 |
2003-05-22 |
Glaxo Group Limited |
Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
|
|
WO2003048181A1
(en)
*
|
2001-12-01 |
2003-06-12 |
Glaxo Group Limited |
17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
|
|
WO2003072592A1
(en)
*
|
2002-01-15 |
2003-09-04 |
Glaxo Group Limited |
17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
|
|
AU2003201693A1
(en)
*
|
2002-01-21 |
2003-09-02 |
Glaxo Group Limited |
Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
|
|
GB0202216D0
(en)
*
|
2002-01-31 |
2002-03-20 |
Glaxo Group Ltd |
Novel compounds
|
|
US20050175545A1
(en)
*
|
2002-02-04 |
2005-08-11 |
Keith Biggadike |
Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
|
|
AU2003244451A1
(en)
*
|
2002-02-04 |
2003-09-02 |
Glaxo Group Limited |
Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
|
|
GB0202635D0
(en)
*
|
2002-02-05 |
2002-03-20 |
Glaxo Wellcome Mfg Pte Ltd |
Formulation containing novel anti-inflammatory androstane derivative
|
|
GB2389530B
(en)
*
|
2002-06-14 |
2007-01-10 |
Cipla Ltd |
Pharmaceutical compositions
|
|
GB0217504D0
(en)
*
|
2002-07-29 |
2002-09-04 |
Novartis Ag |
Organic compounds
|
|
US20060228305A1
(en)
*
|
2003-02-11 |
2006-10-12 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
|
|
AR044519A1
(es)
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
|
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
US7507745B2
(en)
|
2004-02-20 |
2009-03-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
|
|
KR101179393B1
(ko)
*
|
2004-03-23 |
2012-09-07 |
노파르티스 아게 |
제약 조성물
|
|
GB0410712D0
(en)
|
2004-05-13 |
2004-06-16 |
Novartis Ag |
Organic compounds
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
DE102004025966A1
(de)
*
|
2004-05-21 |
2005-12-15 |
Schering Ag |
Estradiol-Prodrugs
|
|
DE102004025985A1
(de)
*
|
2004-05-21 |
2005-12-15 |
Schering Ag |
Estriol- und Estetrol-Prodrugs
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
ATE517908T1
(de)
|
2005-01-10 |
2011-08-15 |
Glaxo Group Ltd |
Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
|
|
GB0507165D0
(en)
*
|
2005-04-08 |
2005-05-18 |
Glaxo Group Ltd |
Novel crystalline pharmaceutical product
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
|
KR20080036632A
(ko)
|
2005-08-08 |
2008-04-28 |
아젠터 디스커버리 리미티드 |
바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
|
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
|
EP2532678A1
(en)
|
2005-10-21 |
2012-12-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
|
GB0523654D0
(en)
*
|
2005-11-21 |
2005-12-28 |
Novartis Ag |
Organic compounds
|
|
GB0523656D0
(en)
*
|
2005-11-21 |
2005-12-28 |
Novartis Ag |
Organic compounds
|
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
GB0603783D0
(en)
*
|
2006-02-24 |
2006-04-05 |
Novartis Ag |
Organic compounds
|
|
RU2457209C2
(ru)
|
2006-04-21 |
2012-07-27 |
Новартис Аг |
Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
|
|
CN101553493B
(zh)
|
2006-07-19 |
2012-07-04 |
阿斯利康(瑞典)有限公司 |
三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途
|
|
GB0615108D0
(en)
*
|
2006-07-28 |
2006-09-06 |
Glaxo Group Ltd |
Novel formulations
|
|
EP1894568A1
(en)
*
|
2006-08-31 |
2008-03-05 |
Novartis AG |
Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
|
|
JP2010504933A
(ja)
|
2006-09-29 |
2010-02-18 |
ノバルティス アーゲー |
Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
|
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
RU2009120229A
(ru)
|
2006-12-19 |
2011-01-27 |
Астразенека Аб (Se) |
Производные хинуклидинола в качестве антагонистов мускариновых рецепторов
|
|
DK2104535T3
(da)
|
2007-01-10 |
2011-04-04 |
Irm Llc |
Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
|
|
AU2008214214B2
(en)
|
2007-02-09 |
2011-09-15 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
|
BRPI0811562A2
(pt)
|
2007-05-07 |
2014-12-09 |
Novartis Ag |
Compostos orgânicos
|
|
PT2444120T
(pt)
|
2007-12-10 |
2018-01-03 |
Novartis Ag |
Análogos da amilorida espirocíclicos como bloqueadores de enac
|
|
PT2231642E
(pt)
|
2008-01-11 |
2014-03-12 |
Novartis Ag |
Pirimidinas como inibidores de quinase
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
BRPI0822693A2
(pt)
|
2008-05-13 |
2015-07-07 |
Astrazeneca Ab |
Derivados de quinuclidina como antagonistas do receptor muscarínico m3
|
|
EP2297106B1
(en)
|
2008-05-27 |
2014-07-16 |
AstraZeneca AB |
Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states
|
|
WO2009150137A2
(en)
|
2008-06-10 |
2009-12-17 |
Novartis Ag |
Organic compounds
|
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
|
MX2011007036A
(es)
|
2008-12-30 |
2011-07-20 |
Pulmagen Therapeutics Inflammation Ltd |
Compuestos de sulfonamida para el tratamiento de trastornos respiratorios.
|
|
WO2010088335A1
(en)
|
2009-01-29 |
2010-08-05 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
|
EP2435462A1
(en)
|
2009-05-29 |
2012-04-04 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
KR20120089643A
(ko)
|
2009-08-12 |
2012-08-13 |
노파르티스 아게 |
헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
|
|
PE20170003A1
(es)
|
2009-08-17 |
2017-03-15 |
Intellikine Llc |
Compuestos heterociclicos y usos de los mismos
|
|
IN2012DN01453A
(cg-RX-API-DMAC10.html)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
|
MX2012004792A
(es)
|
2009-10-22 |
2013-02-01 |
Vertex Pharma |
Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
|
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
EA201391230A1
(ru)
|
2011-02-25 |
2014-01-30 |
АйАрЭм ЭлЭлСи |
Соединения и композиции в качестве ингибиторов trk
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
UY34329A
(es)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
Compuestos de triazolopiridina
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
|
WO2013078440A2
(en)
|
2011-11-23 |
2013-05-30 |
Intellikine, Llc |
Enhanced treatment regimens using mtor inhibitors
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
WO2013149581A1
(en)
|
2012-04-03 |
2013-10-10 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
|
US10155001B2
(en)
|
2013-06-14 |
2018-12-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
RAC1 inhibitors for inducing bronchodilation
|
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
|
JP6433509B2
(ja)
|
2014-04-24 |
2018-12-05 |
ノバルティス アーゲー |
ホスファチジルイノシトール3−キナーゼ阻害薬としてのアミノピラジン誘導体
|
|
PL3134395T3
(pl)
|
2014-04-24 |
2018-07-31 |
Novartis Ag |
Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
|
|
BR112016024484A2
(pt)
|
2014-04-24 |
2017-08-15 |
Novartis Ag |
derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
EP3174869B1
(en)
|
2014-07-31 |
2020-08-19 |
Novartis AG |
Combination therapy of a met inhibitor and an egfr inhibitor
|
|
EP3703065A1
(en)
|
2015-01-20 |
2020-09-02 |
Novartis AG |
Application unlock using a connected physical device and transfer of data therebetween
|
|
EP3111978B1
(en)
|
2015-07-03 |
2021-09-01 |
Novartis AG |
Inhaler adapted to read information stored in a data storage means of a container
|
|
CN108129537B
(zh)
*
|
2017-12-19 |
2022-03-01 |
广州健康元呼吸药物工程技术有限公司 |
一种糖皮质激素异构体及其制备方法和用途
|
|
MX2021015133A
(es)
|
2019-06-10 |
2022-01-24 |
Novartis Ag |
Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
|
|
CR20220060A
(es)
|
2019-08-28 |
2022-03-01 |
Novartis Ag |
Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|